The MPP / MDCS / MOS cohorts

Requests for biological samples and data

The MPP/MDCS Steering Committee welcomes applications from all researchers.

Homepage for detailed instructions: <u>https://www.malmo-kohorter.lu.se/</u>

Please check the following in order to avoid unnecessary delays:


- 1. A final decision can only be obtained following ethical clearance.
- 2. All requests for biological samples must be minimised. <u>Amount and number</u> of samples must be clearly stated. The samples are stored in Malmö (liquid nitrogen and -80°C) and at Region Skåne Biobank facility BD47 in Lund, RS136BD47@skane.se (other samples).
- 3. Specify data requests using the MPP/MDCS/MOS variable lists in Excel (please see homepage, or contact data manager). A final decision will not be made without a specified variable request.
- 4. Personal identity numbers (personnummer) are with few exceptions <u>not transferred</u> from the database to the researcher and never together with other data from MPP/MDCS/MOS.
- 5. When samples and/or data are requested from more than one cohort (MPP, MDCS or MOS), please submit <u>separate applications</u>.
- 6. Data in the Vital status and Diabetes endpoint files do partly originate from Statistics Sweden (Statistiska centralbyrån; SCB) and the Swedish National Diabetes Register (Nationella diabetesregistret; NDR), these sources should be mentioned in publications. SCB has the following requirement for distribution of data: "*I samband med publicering skall SCB:s namn anges i enlighet med god sed*". Similarly, the requirement from NDR is: "*Att korrekta hänvisningar till registret görs i metodavsnitt samt i acknowledgements i publikationen/publikationerna*".
- 7. The applicant will be <u>charged for costs</u> related to biobank and data retrieval. The overhead cost of the University will be added. Please ask for a preliminary estimation or see the <u>homepage</u>.
- 8. Please send the digital application and attachments, including variable lists, to data manager Anders Dahlin (anders.dahlin@med.lu.se), as well as a signed copy of the application.

<u>NB! Results of sample analyses must be transferred</u> to the MPP/MDCS/MOS data manager according to an agreed format when completed!

The MPP/MDCS Steering Committee Olle Melander, chairman

Brief description of the cohorts

- The MPP baseline study consists of 33 346 participants, out of these 7 354 have data and samples from a second screening (6 109 belong to the defined "6-year" cohort) and 581 from a third. In these screenings almost identical questionnaires and lab analyses were employed. A larger rescreening was conducted during 2002-2006 when all participants in the MPP baseline study were invited.
- In total, 30 446 individuals participated in the MDCS baseline study, but about 2300 lack some data or samples, leaving 28 098 participants with complete information, the so called "EPIC cohort". About five years after the baseline screening a follow-up questionnary was sent to all participants in the EPIC cohort, 22 369 responded.
- Every other individual in the MDCS cohort screened between 1991 to 1994 was invited to a cardiovascular (CV) project which included a carotid ultrasound examination for determination of carotid intima-media thickness and plaques, 6 103 participated. Out of these, 3 734 did also take part in the rescreening 2007-2012.
- About 13 000 individuals participated in both MPP and MDCS baseline studies.
- The MOS-study, which started in 2013, consists of children and grandchildren of individuals in the MDC CV study. Data are available from 2644 individuals ("half-time" study).
- The cohorts, including samples collected, are illustrated in the figure below:



REQUEST FOR BIOBANK SAMPLES AND DATA FROM THE MPP / MDCS / MOS COHORTS

1. COHORT			
MPP MDCS MOS			
2. RESPONSIBLE RESEARCHER			
Name	Research location		
Address	E-mail Phone		
Invoicing address (alternatives: 1. "kostnadsställe" and activity (LU), 2. RS	B-ID and clinic (Region Skåne), or 3. org./VAT number, name and address)		
3. PREREQUISITES			
Date of approval of Ethical Committee	Application decision number from Ethical Committee		
4. PROJECT DESCRIPTION			
Project title			
Short project description (aim, study population, methods and analyses, laboratory, statistical power, and time schedule)			
 This application is new (i.e. it is not a supplement to any previous application) This application is a supplement to a previous application with MFM/MKC/MOS registration number: 			
5. REQUESTED BIOLOGICAL SAMPLES (ERYTHROCYTES AND MNL: O	NLY MDCS; FAECES AND URINE: ONLY MOS)		
New sample retrieval Use of previously approved sample			
Requesting results from previous sample analysis carried out b	y (PI):		
Plasma (μl)Serum (μl)Erythrocytes (μl)MNL (μl)	DNA (ng) Faeces (gram) Urine (ul)		
Cohort (samples) MPP base MPP 6 yr screen MPP screen2 MPP screen3 MPP rescr 2002-06 MDCS base MDC CV MDC CV rescr MOS Number of requested samples:			
Mote state and the state and t			
Motivation for amount of requested biological samples			
6. REQUESTED DATA			
Cohort (data) \square MPP base (33 346) \square MPP 6 yr scr (6 109) \square MPP scr2 (1 245) \square MPP scr3 (581)			
$\square MPP rescr (18 240) \qquad \square MDCS base (30 446) \square MDC EPIC (28 098) \square MDC 5yr rescr (22 369) \square MDC CV (6 103)$			
MDC CV rescr (3734) MOS (ongoing)			
Type of requested data Number of individuals (if not given above):			
Which type of identity is wanted?			
Personal number (NB! Not with other data) Biobank or database number Project specific identification number			
Which type of file format is wanted?			
SPSS (default) SAS STATA Excel Text Other:			
7. ATTACHMENTS TO THE APPLICATION			
Att. 1, written description of the research project			
Att. 2, application to Ethical Committee Att. 3, decision by Ethical Committee			
Att. 4, list of data variables			
8. COMMITMENTS, INCL COST FOR SAMPLE RETRIEVAL AND DATA MANAGEMENT			
I am aware that I should return the results from sample analysis after completion of the study (if samples are requested)			
I am aware that a fee will be charged in order to cover sample retrieval and data management and I have filled in the			
invoicing address (see section 2 above)	Yes		

9. SIGNATURES (I HAVE READ AND ACKNOWLEDGE THE TERMS UNDE			
Sigr	ature by applicant	Signature by principal investigator, where pertinent	
Nan	ne in block letters	Name in block letters	
10.1	MPP/MDCS STEERING COMMITTEE DECISIONS		
	Sample extraction approved	Data extraction approved	
Sample extraction denied		Data extraction denied	
Sample extraction approved on condition:		Data extraction approved on condition:	
	1 11		
Price per sample (SEK): + OH		Registration fee (SEK):	+ OH
	Region Skåne's (BD47) costs for extracting samples will be added		+ OH
Date	e and signature by authorized representative of MPP/MDCS	Name in block letters	
11.7	TERMS AND CONDITIONS FOR TRANSFER OF SAMPLES AND INFOR	MATION	
1.	1. The following general terms and conditions prevail between applicants/fellow applicants (jointly referred to as "applicants" below) and The MPP/MDCS Steering Committee for transfer of samples and information from the MPP/MDCS/MOS biobanks and databases (called "Biobank" below).		
2.	2. In signing above, the applicants acknowledge that they agree to and accept the following conditions for the transfer of samples and information from the Biobank. The term "information" includes data collected at the time of specimen collection (including blood analyses, height, weight, blood pressure, diet, and questionnaire data) as well as information acquired by the Biobank thereafter. The applicants may use the samples and information only for the purposes listed in the description of the research project.		
3. a)	3. a) Information and samples will be released for analysis under code. The applicants agree to return the results of all tests and analyses according to an agreed format to the Biobank when completed. Case-control status and other phenotypic information will be released from the Biobank to the applicant only after the results have been deposited with the Biobank.		
b)	b) Information that certain data exists will be public, but deposited results remain the property of the applicant and may be used by the Biobank or by future applicants only by permission of the depositor. Only if and when the depositor so wishes may these results become the property of the Biobank; such an agreement may be included in the decision of The MPP/MDCS Steering Committee		
c)	c) As amounts of biological samples are limited, all requests for samples must include a motivation for the amount of sample requested. Requests for excessive amounts will be negotiated prior to release.		
d)	d) The use of samples or information in research conducted in cooperation with, under the assignment of, under the license of, or under similar conditions in connection with, a commercial company is forbidden unless prior written approval has been obtained from The MPP/MDCS Steering Committee.		
e)	e) The applicant agrees to return any unused portions of samples, including extracted DNA, as soon as the research project has been completed. Following contact with The MPP/MDCS Steering Committee, small portions may instead be destroyed.		
f)	f) The applicants agree not to transfer samples or information to third parties other than those specified as laboratories performing analysis of the samples in the description of the research project.		
4.	Additional samples or information from the research subjetcs, or their relatives, to which received samples or information are connected, may not be acquired without special permission from The MPP/MDCS Steering Committee.		
5.	The applicant will be charged for costs related to biobank and data retrieval. These costs cover retrieval, aliquoting, mainte- nance of the biobank, and data management. The overhead cost of the University will be added. The receiver of samples will also bear the cost of handling and transport (including returned samples) in addition to the costs mentioned above.		
6.	Projects leading to potential patent applications should be performed in collaboration with The MPP/MDCS Steering Committee. The sale or transfer of patent rights or rights related to patent applications for discoveries based on the results of the research project or samples, or any other commercial exploitation of results, are forbidden without prior written approval from The MPP/MDCS Steering Committee.		
7.	The applicants are forbidden to transfer their rights or obligative written approval from The MPP/MDCS Steering Committee.	ons according to this contract to third parties without p	rior
8.	This contract falls under Swedish law. Conflicts arising from this contract will be settled in Swedish court. The information is processed in accordance with Regulation (EU) 2016/679 (General Data Protection Regulation, GDPR).		

12. GENERAL INFORMATION		
This request form should be sent as:	Contact information:	
1) Electronic copy, and	Olle Melander, chairman of The Steering Committee	
2) Signed hardcopy	Lunds universitet	
	Hypertoni och hjärt-kärl sjukdom	
To:	Jan Waldenströms gata 35	
Data manager	SUS Malmö	
Anders Dahlin	SE-205 02 Malmö, Sweden	
Lunds universitet	E-mail: olle.melander@med.lu.se	
Enheten för internmedicin	Phone: +46-(0)40-391209	
Jan Waldenströms gata 15, plan 5	Mobile: +46-(0)40-391221	
SUS Malmö		
SE-205 02 Malmö, Sweden		
E-mail: anders.dahlin@med.lu.se		
Phone: +46-(0)40-332460		